Social networking for the proteome, upgraded | HMS – Harvard Medical School (registration)

Harvard Medical School researchers have mapped the interaction partners for proteins encoded by more than 5,800 genes, representing over a quarter of the human genome, according to a new study published online in Nature on May 17.

The network, dubbed BioPlex 2.0, identifies more than 56,000 unique protein-to-protein interactions87 percent of them previously unknownthe largest such network to date.

Get HMS news here

BioPlex reveals protein communities associated with fundamental cellular processes and diseases such as hypertension and cancer, and highlights new opportunities for efforts to understand human biology and disease.

The work was done in collaboration with Biogen, which also provided partial funding for the study.

A gene isnt just a sequence of a piece of DNA. A gene is also the protein it encodes, and we will never understand the genome until we understand the proteome, said co-senior author Wade Harper, the Bert and Natalie Vallee Professor of Molecular Pathology and chair of the Department of Cell Biology at HMS. BioPlex provides a framework with the depth and breadth of data needed to address this challenge.

This project is an atlas of human protein interactions, spanning almost every aspect of biology, said co-senior author Steven Gygi, professor of cell biology and director of the Thermo Fisher Center for Multiplexed Proteomics at HMS. It creates a social network for each protein and allows us to see not only how proteins interact, but also possible functional roles for previously unknown proteins.

HMS scientists are mapping interaction networks throughoutthe human proteome. Edward Huttlin, instructorin cell biology, explains. Video: Elizabeth Cooney

Bait and prey

Of the roughly 20,000 protein-coding genes in the human genome, scientists have studied only a fraction in detail. To work toward a description of the entire cast of proteins in a cell and the interactions between themknown as the proteome and interactome, respectivelya team led by Harper and Gygi developed BioPlex, a high-throughput approach for the identification of protein interplay.

BioPlex uses so-called affinity purification, in which a single tagged bait protein is expressed in human cells in the laboratory. The bait protein binds with its interaction partners, or prey proteins, which are then fished out from the cell and analyzed using mass spectrometry, a technique that identifies and quantifies proteins based on their unique molecular signatures. In 2015, an initial effort (BioPlex 1.0) used approximately 2,600 different bait proteins, drawn from the Human ORFeome database, to identify nearly 24,000 protein interactions.

In the current study, the team expanded the network to include a total of 5,891 bait proteins, which revealed 56,553 interactions involving 10,961 different proteins. An estimated 87 percent of these interactions have not been previously reported.

Guilt by association

By mapping these interactions, BioPlex 2.0 identifies groups of functionally related proteins, which tend to cluster into tightly interconnected communities. Such guilt-by-association analyses suggested possible roles for previously unknown proteins, as these communities often commingle proteins with both known and unknown functions.

The team mapped numerous protein clusters associated with basic cellular processes, such as DNA transcription and energy production, and a variety of human diseases. Colorectal cancer, for example, appears to be linked to protein networks that play a role in abnormal cell growth, while hypertension is linked to protein networks for ion channels, transcription factors and metabolic enzymes.

With the upgraded network, we can make stronger predictions because we have a more complete picture of the interactions within a cell, said first author Edward Huttlin, instructor of cell biology at HMS. We can pick out statistical patterns in the data that might suggest disease susceptibility for certain proteins, or others that might suggest function or localization properties. It makes a significant portion of the human proteome accessible for study.

Launching point

The entire BioPlex network and accompanying data are publicly available, supporting both large-scale studies of protein interaction and targeted studies of the function of specific proteins.

Although the network serves as the largest collection of such data gathered to date, the authors caution it remains an incomplete model. The current pipeline expresses bait proteins in only one cell type (human embryonic kidney cells) grown under one set of conditions, for example, and distinct interactions may occur in different cell types or microenvironments.

As the network increases in size and more human proteins are used as baits, scientists can better judge the accuracy of each individual protein interaction by considering its context in the larger network. Isolating the same protein complex several times, each time using a different member as a bait, can provide multiple independent experimental observations to confirm each proteins membership.

Moreover, by using prey proteins as bait, many protein interactions can be observed in the opposite direction as well. Both of these scenarios greatly reduce the likelihood that particular interactions were identified due to chance. The team continues to add to BioPlex, with a target goal of around 10,000 bait proteins, which would cover half of the human genome and would further increase the predictive power of the network.

We certainly arent seeing all the interactions, but its a launching point. We think its important to continue to build this map, to see how much of it is reproduced in other cell types under different conditions, to see whether the interactions are similar or dynamic, Gygi said. Because whether youre interested in cancer or neurodegenerative disease, basic development or evolutionary fitnessyou can make new hypotheses and learn something from this network.

This work was supported by the National Institutes of Health (HG006673, DK098285), Biogen and the Canadian Institutes of Health Research.

Co-authors on the study included Raphael J. Bruckner, Joao A. Paulo, Joe R. Cannon, Lily Ting, Kurt Baltier, Greg Colby, Fana Gebreab, Melanie P. Gygi, Hannah Parzen, John Szpyt, Stanley Tam, Gabriela Zarraga, Laura Pontano-Vaites, Sharan Swarup, Anne E. White, Devin K. Schweppe, Ramin Rad, Brian K. Erickson, Robert A. Obar, K.G. Guruharsha, Kejie Li and Spyros Artavanis-Tsakonas.

Read this article:
Social networking for the proteome, upgraded | HMS - Harvard Medical School (registration)

Veterinary Biochemistry Analyzers Market Key … – Digital Journal – Digital Journal

This press release was orginally distributed by SBWire

Albany, NY -- (SBWIRE) -- 05/19/2017 -- Veterinary Biochemistry Analyzers Market: Overview

Veterinary biochemistry analyzers enable testing to be performed quickly and accurately for immediate diagnosis and health check for animals. They are also used in emergency situation, and routine testing. Increasing incidences of disease outbreak in animals and technological advancements are expected to drive the veterinary biochemistry analyzers market. Additionally, growing awareness regarding animal health and rise in investment opportunities together form strong market prospects for veterinary biochemistry analyzers, especially in the developing countries.

View Report @ http://www.transparencymarketresearch.com/veterinary-biochemistry-analyzers-market.html

The threats such as foot and mouth disease (FMD), as well as agents that affect animals and humans, such as bovine tuberculosis and paratuberculosis, anthrax, avian influenza, bovine spongiform encephalopathy (BSE) and West Nile virus are responsible for rise in importance of need for veterinary disease diagnostics eventually propelling the market growth.

Most veterinary laboratories typically provide a basic panel of tests. The veterinary biochemistry analysis may be performed in-house at the veterinarian's clinic or at a specialized test facility in another location depending on the need of test type to be performed as well as availability of equipment in that particular facility. Advancements in the analyzers technology is anticipated to fuel fueled the market growth due to the availability of faster and cheaper microchips with increase in acceptance level of pet owners for laboratory testing.

Veterinary Biochemistry Analyzers Market: Segmentation

The global veterinary biochemistry analyzers market can be segmented on the basis of product type, test type, animal type, end-users and geography. Test types include clinical chemistry, critical care and blood gases, electrolytes, glucose, lactate and blood and urine tests. Other tests include: tests for anemia, endocrine function; cancer, viral pathogens such as calicivirus (CaCV), canine adenovirus type-1 (CAV-1), coronavirus, adenovirus, parvovirus, rotavirus, rabies, West Nile Virus, etc.; and bacteria and parasites such as E. coli, heartworm, cryptosporidia, hookworm, leptospirosis, leishmania, Lyme disease, tapeworm and roundworm. Chemical analysis of urine may include determination of specific gravity and pH level, measurement of the amount of glucose, protein, or fragmented blood cells, assisting in identification of injury, disease, or defects.

Analysis of the numbers and structure of blood cells is important in the diagnosis and monitoring of disease and infection. Blood samples are usually taken by the veterinarian or a veterinary technician for analysis. Product types include fully automated analyzers, semi-automated analyzers, hematology analyzers, urine analyzers amongst others.

End-users segment includes veterinary clinics, pet hospitals and animal research institutes. Companion animal and farm animal form two segments for animal type.

Veterinary Biochemistry Analyzers Market: Region-wise Outlook

Geographically, the veterinary biochemistry analyzers market across the globe can be segmented into four major regions, namely, North America, Europe, Asia Pacific and Rest of the World. North America is expected to lead the market with maximum share followed by Europe attributed to the increasing companion animal population and positive trends towards healthcare expenditure for animals in these regions.

Veterinary Biochemistry Analyzers Market: Key Entities

Major players contributing to the global veterinary biochemistry analyzers comprise Abaxis,Inc., Heska, Diagno-Vision Products Corporation, Idexx Laboratories, Inc., Mindray Medical International Limited, Neogen Corporation, Thermo Fischer Scientific, Virbac SA, Woodley Equipment Company Ltd., Zoetis, Inc.

Get accurate market forecast and analysis on the Veterinary Biochemistry Analyzers Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11888

Univerities such as the University of Minnesota Veterinary Diagnostic Laboratory (VDL), which is fully accredited by the American Association of Veterinary Laboratory Diagnosticians, provide quality diagnostic services such as bacteriology, necropsy, electron microscopy, serology, clinical chemistry, histopathology, endocrinology, virology, immunohistochemistry, parasitology, toxicology and molecular diagnostics. VDL is also engaged in training future diagnosticians and veterinarians.

For more information on this press release visit: http://www.sbwire.com/press-releases/veterinary-biochemistry-analyzers-market-key-trends-industry-forecast-2023-808303.htm

See original here:
Veterinary Biochemistry Analyzers Market Key ... - Digital Journal - Digital Journal

‘Grey’s Anatomy’: Find out which doctor just left the show – USA TODAY

Jerrika Hinton took to Instagram to express just how grateful she is. USA TODAY

Spoiler alert! The following contains spoilers from Thursday's season finale ofGrey's Anatomy,"Ring of Fire."

Another doctor is leaving Grey Sloan Memorial Hospital.

In a bombastic finale to the show's 13th season, it was revealed that Dr. Stephanie Edwards (Jerrika Hinton) was alive after last week's cliffhanger, but also that she is leaving the hospital, and the show, after enduring burns during a traumatic night.

We'll miss you, Edwards!(Photo: Richard Cartwright, ABC)

Last week's episode found a rapist loose in the hospital, who first holds Edwards at knife-point, then sets a fire to attempt to escape the hospital and even takes a young girl hostage. Edwards is able to save the girl but suffers severe burns in the process. In the finale, confined to her hospital bed, Edwards tells her mentorDr. Richard Webber (James Pickens Jr.), "I quit."

And though Edwards will be missed, her method of exit is rare on a show known for its tragic deaths. In a goodbye note on her Instagram, Hinton noted how great it was that Edwards got to choose her own path.

"I am eternally thankful for five seasons of (Grey's Anatomy) and a graceful departure that underscores the courage it takes to choose yourself," Hinton wrote. "That Stephanie literally walks through fire to reach freedom her freedom inspires me. It also makes me curious: What does freedom look like for you, dear viewer? After all, its not only the heroics that make her brave, its her finally seeing (and seeking) a better path."

"You fans and viewers are some of the most devoted folks Ive ever met," she went on. "Thank you for your endless energy. Bosslady Shonda, Queen Debbie, and entire (Grey's Anatomy) cast and crew forever remain in my heart. The #Shondaland family is a mighty, winding forest. I look forward to seeing you all in another clearing."

See her whole note below.

Read or Share this story: https://usat.ly/2qB3lL4

Go here to see the original:
'Grey's Anatomy': Find out which doctor just left the show - USA TODAY

Grey’s Inferno? 6 Suggestions for the Grey’s Anatomy Firefighter Spin-Off – TV Guide (blog)

Now Playing Grey's Anatomy Is Spinning Off Into the Fire Department

Thirteen seasons in, Grey's Anatomy is still hot -- so hot that it's getting its second spin-off next season focused on Seattle's finest (and probably horniest) firefighters.

Details are scarce on the project, but what we do know: It received a straight-to-series order and will debut sometime next year. And in lieu of Shonda Rhimes, Grey's executive producer Stacy McKee will serve as showrunner -- which makes sense since she penned Thursday's fiery Season 13 finale. That's probably what sparked the idea! (#sorrynotsorry) The show's currently untitled, but don't worry, Shondaland, we've got some suggestions for you.

Add the new Fall shows to your Watchlist now!

1. Sea(ttle) of Flames Look, anything like Seattle Fire is too easy and Rhimes is going to want to distance herself as much as possible from comparisons to Dick Wolf's One Chicago franchise, which she's already halfway to replicating. Sea(ttle) of Flames covers a lot of territory: The fire element, duh, the city, and the city's wet reputation. I'll refrain from the low-hanging "Why do we need firefighters anyway with the rain?" joke.

2. Scarlett's BlazeThis is ideal if Shondaland wants to continue its colored moniker nomenclature. Scarlett's a shade of red and a name! Grey's very briefly introduced "Firefighter Carroll" (Stephanie Czajkowski) in Thursday's finale, but it's unclear if she'd be the spin-off's lead right now. Nevertheless, Scarlett could still be her first name, while "blaze" would be a nod to the eventual use of Bon Jovi's "Blaze of Glory" (you know Rhimes loves her music!).

Furthermore, Rhimes' new, generically titled legal drama For the People was formerly dubbed Mother Court (LOL) and Black's Law. Since the slow is slated for midseason, it's not too late to retroactively make this the ChiJu of the Greysverse and revert to Black's Law. (The eventual cop spin-off would have a blue-hued name, obviously.)

3. Grey's InfernoOr they could retain the "Grey's" name for easy-to-recognize familiarity in the age of Peak TV (and would it surprise anyone if Meredith discovered she had another sister at this point?). Plus, everyone knows the 10th circle of hell is Shondaland's catastrophe-prone Seattle.

4. Byrnes' Ashes Non-colored, no Grey relation, but still pun-tastic. Alternate, far-more-literal spelling: Burns' Ashes.

5. How to Get Away with PyromaniaIn a Law & Order: Criminal Intent-esque twist, the show would be told from the perspectives of both the people who start fires around Seattle and the firefighters who try to put them out. (Fun fact: Czajkowski guest-starred on How to Get Away with Murder in 2015.)

6. Hose Before Bros The spin-off will almost definitely feature a female lead to join the ranks of Shondaland badass leading ladies Meredith Grey, Olivia Pope, Annalise Keating, Addison Montgomery et al., and it will definitely cover the team's personal lives (the logline promises the show will follow "heroic firefighters as they risk their lives and their hearts both in the line of duty and off the clock"). After getting burned (!) by a former flame (!!), our heroine will have a renewed focus on her career, coining the titular mantra, but then a new hoseman joins the firehouse, and well, you know.

The Grey's spin-off will premiere next year.

More here:
Grey's Inferno? 6 Suggestions for the Grey's Anatomy Firefighter Spin-Off - TV Guide (blog)

The anatomy of ad copy relevance: The new Google standard – Search Engine Land

Recently, enterprise-focused Google representatives have been encouraging a metric called Relevance, which is believed to be one of the three main factors that make upQuality Score. Relevance is a metric which evaluates how pertinent your ad creative is to your account structure and keywords.

At AdBasis, we have spent Q1 speaking with enterprise-level advertisers about changes being implemented to account structures and to ad units (creative) in order to improve their relevancy scores as recommended by Google. This often means that advertisers need to implement hyper-specific ads to every ad group in their accounts.

As a result, we have seen the demand for scaled ad implementations, ad unit management and creative optimization grow dramatically. This article is designed to give you a standard for what your creative should look like within every ad group. Im going to dissect the anatomy of ad structure, showcase some best practices and provide some additional commentary.

AdWords accounts are growing larger and larger. I am not talking about overall spend I am talking about the number of campaigns and ad groups within a single AdWords account.Whether youre using Single Keyword Ad Groups (SKAGs) or something close to it, chances are the number of ad groups in your account has grown significantly. SEMs everywhere are hit with a new set ofchallenges related to this shift.

If your account has been evolving, chances are your existing creative is fragmented and unmeasurable; this is a major problem. One of the biggest challenges is the management, implementation, measurement and optimization of the associated ad units. And now, with Googles new push for extremely granular ad copy relevance, your generic ad copy will no longer work.

So, what does a high-quality search ad look like?

Just as the human body can be dissected and understood, so can your search ads. Here we will evaluate the different organs that make up a search ad and how they can be altered to improve performance. Understanding how Google will evaluate your ad copy based on keyword + search term is vital to understanding how to structure your creative in bulk.

The elements of a search ad that are most vital to determining relevance are as follows:

In order to combat the problem of fragmented and differing creative at the ad group level, standardization through dynamic ad templates across similarly behaving ad groups is a great technique.

What does that mean? It means designing ad copy templatessuch that the search term can be inserted based on the ad group, but the ad copy surrounding your search term is relevant, flexible and testable.This can be achievedusing feed-based technologies to dynamically insert ad content based on ad group or campaign.

(Im notgoing to get into tech setup since thats beyond the scope of this article, but you can learn more about generating feeds and feed-based technologies here.)

Okay, so what should your dynamic ad templates look like?

In the examples below, I willshowcase how feeds can be used to dynamically insert unique creative based on the ad group or campaign (ad group and campaign are the two levels of hierarchy to which creative can be mapped).

The highlighted text in the examplesbelow represents ad copy that is not static; it is written in a way that can be swapped out orchanged based on the needs of the advertiser and how the account is set up. Imagine the highlighted elements are changing based on your ad group.

The goal of these templates is to map search terms to specific ad groups in ways that make sense in ad copy.

The company in the examplebelow has ad groups for specific action verbs (Browse, Search, Find and so on) and Makes/Models of vehicles (e.g., Toyota, Honda, Mercedes). From this, they could create a feed of action verbs by ad group, a list of Makes by ad group, and a list of Models by ad group. These variables would change dynamically based on the content in their feeds.

As you can see, this particular ad copy template would work across hundreds or thousands of ad groups which are geared toward different keywords and Makes/Models. Youd keep the quality of your ad copy relevance and be able to measure the performance of this creative template.

Through the use of dynamic templates, e-commerce brands can implement, manage and measure ad copy in bulk. Knowing if BOGO vs. 50% Off works best for particular audiences or product categories is vital information. But often, this is very difficult to execute at scale without sacrificing ad relevance.

Here is an example of a scaled ad template that can be used by e-commerce brands. The makeup of this ad template includes an audience variable (Men or Women), product category variable (Shoes, Shirts, Pants) and discount percentage (mapped to the product category).

These elements can be shifted throughout the ad and tested across ad groups/campaigns dynamically. Generating a feed of your dynamic elements and mapping them to campaigns or ad groups is crucial to standardization and measurement of ad creative at scale.

SaaS companies are unique because often, they only offer a single product. In many instances, SaaS companies will position the same product in different ways and will segment campaigns by the value proposition someone is searching for.

This provides a unique set of challenges. Another approach to dynamic ad copy templates isnt inserting a search term, but rather entire Headlines, Pathways, Descriptions and so on.

Below, this SaaS company is dynamically inserting the Headline 1 and Description based on the ad group. This gives them the opportunity to test Pathways and Headline 2 without sacrificing the customized Headline 1 and Description theyve written.

The use of dynamic ad templates across ad groups and campaigns affords you the opportunity to test your ads in two main ways:

This approach is designed to provide SEMs with an approach that is flexible enough to test across ad groups/campaigns (implement at scale) but specific enough to deliver extremely relevant ads to all searchers. Its not an easy task, but hopefully, this article will get the creative juices flowing on what technology options are out there to help improve your ad copy relevance.

Some opinions expressed in this article may be those of a guest author and not necessarily Search Engine Land. Staff authors are listed here.

Visit link:
The anatomy of ad copy relevance: The new Google standard - Search Engine Land

Anatomy of an Upfront: Behind the Scenes of NBCU’s Road to Radio City – AdAge.com

Every spring the big TV networks mount elaborate stage shows to promote their new seasons to ad buyers, trying to establish the best possible position before beginning talks for all the upcoming commercial time. Some buyers may just as soon skip the spectacle, but networks still consider them a key tool for framing their offering.

For NBC Universal, the stakes are some $6 billion in ad commitments that Linda Yaccarino, chairman of advertising sales and client partnerships, will negotiate in the weeks following the presentation.

NBC's show at Radio City Music Hall ultimately included 10 confetti cannons, six pyrotechnics cannons and over 100 hours of rehearsal. It left out the planned dancing football players and trampoline artists when John Shea, creative director of the event, cut them at 10 p.m. the night before.

Ad Age followed NBC Universal's team for the three months leading up to the annual pitch to see firsthand what it takes to pull it all off. Watch the video for an exclusive behind-the-scenes look.

By Jeanine Poggi, Nate Skid and David Hall.

Read more here:
Anatomy of an Upfront: Behind the Scenes of NBCU's Road to Radio City - AdAge.com

Thanks to Genetic Testing, Everyone Could Soon Have a Pre-Existing Condition – Slate Magazine

A quick cheek swab and youre well on your way to learning quite a bit about your genetic risk factors.

fotoquique/iStock

As currently written, the American Health Care Act allows states to opt out of the popular Obamacare provision that bans insurers from discriminating against people with pre-existing conditions. Twenty-seven percent of adult Americans under the age of 65 have a declinable pre-existing condition, according to the Kaiser Family Foundation, and if the AHCA becomes law, any number of them could become uninsured. The guiding GOP arithmetic takes as a given that people should pre-emptively pony up for conditions beyond their controlincluding, yes, having a second X chromosome. Millions more have conditionsfrom asthma to the ever-inconvenient urinary tract infectionthat could also jack up the rate of coverage, making insurance prohibitively expensive.

What their calculations dont yet consider are the could-be conditions embedded in our DNA. Our genomes provide a window into scores of genetic risk factors that have yet to present as full-fledged pre-existing conditions. If the GOP insists that people can be charged differently depending on their current health, whats to say theyll stop short of asserting that we could be charged according to our genomes?

The personal genetics revolution is well-underway. More Americans than ever have access to the information contained in their genetic material. When the Affordable Care Act passed in 2010, the cost of sequencing the 3 billion As, Cs, Gs, and Ts that comprise the human genome rang in at $50,000. Today, that price tag has plummeted to $1,000 with promises of a $100 genome in the near future. Already a mere $99 and a dab of spittle will give consumers a good sense of their genetic risk factors from private genetic testing company 23andMe. Last month, the company received Food and Drug Administration approval to test for predispositions to 10 medical conditions. And even before that came through, customers could upload the raw DNA data generated by 23andMe into interpretation only services like Promethease for a DIY disease risk assessment.

And thats just personal use of genetic informationthe current $1,000 price tag means its already accessible in many medical settings. The question now turns to how the data deluge brought on by the genomics age will be used. Personal genetics can empower patients, doctors, and researchers to make more informed decisions around health care. But while this information could help us make better medical choices, it could also be used to fine-tune insurance algorithms, calculating premiums on a sliding scale of genetic risk.

Americans saw this trade-off coming. The Human Genome Project spurred concerns around genetic discrimination in the 1990s. Over a decade before Obamacares pre-existing conditions protections, patient and civil rights organizations came together to press for protections against genetic discrimination. Thirteen years of advocacy efforts led to the bipartisan passage of the Genetic Information Nondiscrimination Act of 2008. GINA prohibits employers and health insurers from using genetics to influence hiring decisions and insurance coverage.

The legislation was celebrated as the first major civil-rights bill of the century. It eased concerns around genetic discrimination to ultimately encourage people to take advantage of emerging genetic technologies and therapies. GINAs protections helped advance genome research, and today millions of Americans have submitted genetic samples for testing. A government-funded $215 million Precision Medicine Initiative is now underway with the goal of collecting genetic and health data from over 1 million Americans to better inform biomedical research.

That means millions of genotypes that can be used by clinicians and researchers to home in on and characterize genes linked to specific diseases. That also means millions of genotypes that could be factored into the underwriting calculus that prioritizes profits over patients.

Whats to say the GOP will stop short of asserting that we could be charged according to our genomes?

Life, disability, and long-term care insurance, which are not covered under GINAs provisions, already use genetic testing results to deny coverage to otherwise healthy individuals. And when it comes to health insurance, GINA isnt perfect. The legislation only protects people who are genetically predisposed to a disease if they are asymptomatic. Once a person begins showing symptoms, GINA no longer matters. But for a while, Obamacare closed that loophole. When it was enacted, personal genetics was still in its infancy23andMe had less than 50,000 customers at a price tag of $999, and AncestryDNA had yet to launch. So in the years since the ACAs passage, shoring up protections against genetic discrimination has received little legislative attention.

Obamacare repeal reopens the gray area between genetic predisposition and a pre-existing condition. The AHCAs MacArthur amendment would require that states opting out of Obamacares pre-existing conditions rule set up high-risk pools for sick people who incur higher medical costs. But what sick actually means is increasingly up for debate. Does a BRCA1 mutation, which portends a 55 percent to 65 percent risk of developing breast cancer by the age of 70, count as a pre-existing condition when youre 30? When youre 60?

DNA doesnt encode certain destiny: Carrying the BRCA1 mutation offers no more clarity than the percentage given above. But without the ACA, GINA is the only thing stopping insurance companies from practicing genetic determinism when they decide what conditions warrant higher premiums or coverage denial. Republicans, who control every branch of government, have shown that they believe different people should be required to pay different amounts on the basis of what essentially amounts to dumb luck. And we already know they have little interest in regulating corporate interests. Besides, nobody dies because they don't have access to health care, remember?

Even with GINA and Obamacare protections still in place, Americans remain wary of participating in whole-genome sequencing studies, citing fears of discrimination from life insurance companies. Their skepticism is warranted: For all its attributes, the ACA paradoxically opened a GINA loophole by encouraging employer health care plans to offer discounts for participating in workplace wellness programs. GOP lawmakers recently seized on this idea, introducing legislation to compel employees to share genetic test results with their employers.

We already know the current government is not much interested in sciencebut if that science involves calculating maximizing profit margins at the expense of patient empowerment, they just might perk up.

Read the original here:
Thanks to Genetic Testing, Everyone Could Soon Have a Pre-Existing Condition - Slate Magazine

Data from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor … – GlobeNewswire (press release)

May 18, 2017 06:00 ET | Source: NewLink Genetics Corporation Updated NewLink Infographic for ASCO and EHA.pdf

AMES, Iowa, May 18, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic agents for patients with newly diagnosed acute myelogenous leukemia (AML), is now available on the website of the European Hematology Association (EHA) Annual Congress.

An infographic accompanying this announcement is available athttp://www.globenewswire.com/NewsRoom/AttachmentNg/8a3b562f-28b3-4526-baaf-95974cd8eb4f

These data to be presented at the EHA Congress further highlight clinical results presented at AACR in April and to be presented at ASCO in June, supporting the hypothesis that the IDO pathway is central to immune suppression in cancer, said Charles J. Link, Jr., M.D., Chief Executive Officer and Chief Scientific Officer. NewLink Genetics has two separate and distinct types of IDO pathway inhibitors in clinical development. Indoximod, which is wholly owned by NewLink Genetics, has a proposed differentiated mechanism within the IDO pathway and acts as a tryptophan mimetic having a direct effect on immune cells to reverse immune suppression used by cancer to protect itself.

Indoximod in combination with chemotherapeutic agents

Initial results from the Phase 1b portion of a Phase 1b/randomized Phase 2a trial of indoximod in combination with chemotherapeutic agents, idarubicin and cytarabine, for patients with newly diagnosed AML will be presented as an e-poster (Abstract number E-912) by Ashkan Emadi, M.D., Ph.D., Associate Professor of the University of Maryland Greenebaum Comprehensive Cancer Center, at EHA in Madrid on Friday, June 23, 2017, 9:30 AM to Saturday, June 24, 7:00 PM CET and is titled: Indoximod in Combination with Idarubicin and Cytarabine for Upfront Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Phase 1 Report.

This study uses a conventional remission induction and consolidation protocol for patients with newly diagnosed AML. Indoximod is given orally starting on day 8 of induction onward. The Phase 1 portion evaluated three dose levels of indoximod (600 mg, 1000 mg, 1200 mg) in combination with the standard of care 7+3 chemotherapy. Twelve patients were enrolled, as of March 1, 2017. The results indicate indoximod does not appear to add significant toxicity to standard remission induction and consolidation therapy for patients with newly diagnosed AML. Initial data suggest a low rate of minimal residual disease (MRD-neg) after one cycle of induction chemotherapy.

Nicholas N. Vahanian, M.D., President and Chief Medical Officer added, Importantly, these data support further clinical investigation of our IDO pathway inhibitors in combination with currently available therapies, such as chemotherapy for patients with newly diagnosed Acute Myeloid Leukemia (AML).

Key findings presented from the study include:

About Indoximod Indoximod is an investigational, orally available small molecule targeting the IDO pathway. The IDO pathway is one of the key immuno-oncology targets involved in regulating the tumor microenvironment and immune escape.

NewLink Genetics is currently evaluating indoximod in multiple combination studies for patients with various types of cancer including melanoma, acute myeloid leukemia, pancreatic cancer and prostate cancer.

About NewLink Genetics Corporation NewLink Geneticsis a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.NewLink Genetics'product candidates are designed to harness multiple components of the immune system to combat cancer.For more information, please visit http://www.newlinkgenetics.com.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties.All statements, other than statements of historical fact, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.These forward-looking statements include, among others, statements about results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact.Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink Genetics makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics Annual Report on Form 10-K for the year endedDecember 31, 2016and other reports filed with theU.S. Securities and Exchange Commission(SEC).The forward-looking statements in this press release represent NewLink Genetics views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change.However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.

Related Articles

NewLink Genetics Corporation

Ames, Iowa, UNITED STATES

http://www.linkp.com

Updated NewLink Infographic for ASCO and EHA.pdf

FILE URL | Copy the link below

NewLink Genetics Corporation Logo

LOGO URL | Copy the link below

Formats available:

Continue reading here:
Data from Clinical Study of NewLink Genetics' IDO Pathway Inhibitor ... - GlobeNewswire (press release)

Data from Clinical Studies of NewLink Genetics’ Two Distinct IDO … – GlobeNewswire (press release)

May 17, 2017 17:05 ET | Source: NewLink Genetics Corporation NewLink Infographic ASCO.pdf

AMES, Iowa, May 17, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and navoximod (GDC-0919), used in combination with other agents, are now available on the website of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

An infographic accompanying this announcement is available athttp://www.globenewswire.com/NewsRoom/AttachmentNg/b945495b-6286-4184-881f-b4ea49aa46b4

The IDO pathway is a key immuno-oncology target and NewLink Genetics has two separate and distinct IDO pathway inhibitors in clinical development.Indoximod, which is wholly owned by NewLink Genetics, has a proposed differentiated mechanism within the IDO pathway and acts as a tryptophan mimetic having a direct effect on immune cells to reverse immune suppression used by cancer to protect itself. Navoximod is our direct enzymatic inhibitor of IDO and is partnered with Genentech/Roche, said Charles J. Link, Jr., M.D., Chief Executive Officer and Chief Scientific Officer of NewLink Genetics.

Indoximod in combination with the therapeutic cancer vaccine, PROVENGE

Results from a randomized, double-blind, placebo-controlled, multi-institutional Phase 2 investigator initiated study with indoximod in combination with the therapeutic cancer vaccine, PROVENGE (sipuleucel-T), for patients with metastatic castration resistant prostate cancer will be presented as a poster (Abstract number 3066) by Gautam Gopalji Jha, M.D., Adjunct Assistant Professor, Division of Hematology and Oncology, University of Minnesota, at ASCO in Chicago on Monday, June 5, 2017, 8:00 a.m. 11:30 a.m. CT, titled, A phase 2 randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC).

In the study, forty-six patients were randomized into two arms to receive either twice daily oral indoximod (n=22) or placebo (n=24) for 6 months beginning the day after the third and final PROVENGE infusion. Conclusions indicate that treatment with the IDO pathway inhibitor, indoximod, post PROVENGE therapy, leads to significant improvement in radiographic progression free survival (rPFS) when compared to placebo and is well-tolerated.

Key findings presented from the study include:

These data further support the hypothesis that targeting the IDO Pathway in combination with a broad backbone of treatment regimens including chemotherapy, anti-PD-1 antibodies and therapeutic vaccines across multiple indications has the potential to provide meaningful clinical benefit without compromising tolerability, commented Nicholas N. Vahanian, M.D., President and Chief Medical Officer of NewLink Genetics.

Navoximod in combination with TECENTRIQ (atezolizumab) in multiple solid tumors

Initial data from a Phase 1b dose-escalation study of navoximod in combination with TECENTRIQ for patients with locally advanced or metastatic solid tumors conducted by our partner, Genentech/Roche, will be presented in an oral presentation (Abstract number 105) by Howard A. Skip Burris, III, M.D., President Clinical Operations and Chief Medical Officer, Sarah Cannon Research Institute, at ASCO in Chicago on Sunday, June 4, 2017, 10:24 a.m. CT. The presentation is titled, A phase 1b dose-escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients with locally advanced or metastatic solid tumors.

This Phase 1b, open-label, dose-escalation study is designed to characterize safety and tolerability. Secondary objectives include identifying a maximum tolerated dose (MTD) and recommended Phase 2 dose, and evaluating pharmacokinetics, pharmacodynamics, and anti-tumor activity. Patients were given TECENTRIQ (1200 mg IV every 3 weeks) and escalating doses of navoximod (orally twice daily, for 21 days) using a standard 3+3 design. Initial results from this study (n=52, non-selected heterogeneous population during the dose escalation) found the combination was generally well-tolerated, with peripheral IDO1 modulation, and some early activity signals. Patients were previously treated with prior systemic therapies with a median number of 3 and a range of 1-9. Two patients also received prior immunotherapy.

The design of the trial includes the initial dose-escalation phase reported in this abstract, followed by disease-specific expansion cohorts (enrollment target is 305 patients) for patients with select tumor types including non-small-cell lung cancer (NSCLC), renal cell cancer (RCC), urothelial bladder cancer (UBC), triple negative breast cancer (TNBC), to further evaluate safety, response, and peripheral and tumor pharmacodynamics. Updates for this study will continue to be reported by Genentech/Roche.

Dr. Vahanian continued, We are encouraged by the clinical profile for the combination of navoximod and atezolizumab from the first phase of this combination trial and look forward to the data for the disease-specific expansion cohorts which are currently accruing patients.

About NewLink Genetics Corporation

NewLink Geneticsis a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer.NewLink Genetics'product candidates are designed to harness multiple components of the immune system to combat cancer.For more information, please visit http://www.newlinkgenetics.com.

PROVENGE is a registered trademark of Dendreon/Valeant Pharmaceuticals International, Inc. TECENTRIQ is a registered trademark of Genentech, Inc.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties.All statements, other than statements of historical fact, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.These forward-looking statements include, among others, statements about results of its clinical trials for product candidates; its timing of release of data from ongoing clinical studies; its plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact.Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink Genetics makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics Annual Report on Form 10-K for the year endedDecember 31, 2016and other reports filed with theU.S. Securities and Exchange Commission(SEC).The forward-looking statements in this press release represent NewLink Genetics views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change.However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.

Related Articles

Read more from the original source:
Data from Clinical Studies of NewLink Genetics' Two Distinct IDO ... - GlobeNewswire (press release)

Genetic Health Information Network Summit Will Address Precision Medicine Challenges – PR Newswire (press release)

Unique in both its broad engagement of healthcare stakeholders and its focus on practical solutions to real-world challenges in precision medicine, the invitation-only event will convene leading health plans, clinicians, hospital systems, researchers, policy makers, laboratories, technology vendors and pharmaceutical companies, as well as patients and advocates.

Together, these stakeholders will work to develop action plans to:

"This event is not about simplistic answers, nor debate for its own sake. The goal is to engage in an open, honest dialog that produces clear action plans to improve the Genetic Health Information Network together," said Gillian Hooker, PhD, Concert's vice president of clinical development. "Ultimately, we all want a healthcare system that delivers on the promise of precision medicine to every patient who needs it. In order to do that, we need to work together. We're committed to doing our part to make that happen, both in preparation for the summit, and in facilitating action that will follow it."

The event's organizing committee includes members from across the healthcare landscape. They include:

"Despite the tremendous promise of precision medicine to improve human health, the field suffers from a dearth of data and the digital infrastructure to effectively study the impact of precision diagnostics, drugs and other interventions on healthcare outcomes," said Carlos Bustamante, PhD. "The collaboration represented by this summit is exactly what's needed to change that."

More information on the Summit can be found at http://www.geneticnetworksummit.com.

To advance the industry-wide discussion about improving the Genetic Health Information Network, Concert Genetics published a white paper earlier this year on the state of the Genetic Health Information Network and top opportunities to connect and enhance the network to better integrate precision medicine into the healthcare system. More on that document can be found here: http://www.concertgenetics.com/network.

About Concert GeneticsConcert Genetics provides software and analytic tools to connect, simplify and unify the world of genetic testing for hospital and health systems, clinicians, health plans, labs and governing organizations. Concert's unique applications are built on a market-leading database that combines its index of the entire U.S.-based clinical genetic testing market today more than 70,000 testing products with other enriched data, such as genetic testing claims data from more than 100 million insured members. This data powers the leading genetic test search tool, specialized industry benchmarking and nuanced analysis of market dynamics. Concert aims to connect the disparate stakeholders in the healthcare community to help unlock the full potential of genetic testing for delivering precision medicine. Learn more at http://www.ConcertGenetics.com.

Media Contact:Erin George erin@lovell.com 615-946-9914

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genetic-health-information-network-summit-will-address-precision-medicine-challenges-300459834.html

SOURCE Concert Genetics

http://www.ConcertGenetics.com

Read the original here:
Genetic Health Information Network Summit Will Address Precision Medicine Challenges - PR Newswire (press release)